Cytosorbents Corp Stock OTC Bulletin Board
Stocks
CTSO
US23283X1072
Advanced Medical Equipment & Technology
| Market Cap | 29.91M 25.8M 23.72M 22.33M 41.96M 2.82B 42.31M 281M 109M 1.39B 112M 110M 4.79B | P/E 2026 * |
-2.58x | P/E 2027 * | 15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 29.91M 25.8M 23.72M 22.33M 41.96M 2.82B 42.31M 281M 109M 1.39B 112M 110M 4.79B | EV / Sales 2026 * |
0.78x | EV / Sales 2027 * | 0.63x |
| Free-Float |
85.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytosorbents Corp
| 1 day | -6.91% |
| Manager | Title | Age | Since |
|---|---|---|---|
Phillip Chan
CEO | Chief Executive Officer | 55 | 2008-07-23 |
Peter Mariani
DFI | Director of Finance/CFO | 62 | 2024-08-13 |
Vincent Capponi
PSD | President | 68 | 2020-04-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Bator
CHM | Chairman | 62 | - |
Phillip Chan
BRD | Director/Board Member | 55 | 2008-12-31 |
Edward Jones
BRD | Director/Board Member | 77 | 2011-07-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.91% | -.--% | - | - | 32.54M | |
| -2.31% | -4.22% | +18.30% | -14.07% | 176B | |
| -3.57% | -2.39% | -21.47% | +22.11% | 148B | |
| -1.98% | -3.20% | -9.19% | -26.48% | 128B | |
| -4.20% | -7.01% | -55.81% | -17.25% | 69.74B | |
| -2.14% | +0.81% | +18.30% | -5.72% | 51B | |
| -1.84% | -1.28% | -24.46% | -34.38% | 45.7B | |
| -3.12% | -5.54% | +7.10% | +2.64% | 36.25B | |
| -0.98% | -1.70% | +4.66% | +32.62% | 35.4B | |
| -3.29% | -4.09% | -14.04% | -22.25% | 28.76B | |
| Average | -2.55% | -3.15% | -8.51% | -6.98% | 79.84B | |
| Weighted average by Cap. | -2.20% | -3.31% | -7.23% | -7.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.26M 33.01M 30.35M 28.57M 53.68M 3.61B 54.13M 360M 140M 1.77B 144M 141M 6.13B | 47.12M 40.65M 37.38M 35.18M 66.11M 4.45B 66.66M 443M 172M 2.18B 177M 173M 7.55B |
| Net income | -11.74M -10.13M -9.31M -8.77M -16.47M -1.11B -16.61M -110M -42.96M -544M -44.07M -43.12M -1.88B | 2.37M 2.05M 1.88M 1.77M 3.33M 224M 3.36M 22.3M 8.68M 110M 8.91M 8.72M 380M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
